579 related articles for article (PubMed ID: 18279040)
1. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
2. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
Gentry CA; Williams RJ
Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
5. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
Tamma PD; Turnbull AE; Milstone AM; Hsu AJ; Carroll KC; Cosgrove SE
Clin Infect Dis; 2012 Sep; 55(6):799-806. PubMed ID: 22696019
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
Yamagishi Y; Terada M; Ohki E; Miura Y; Umemura T; Mikamo H
J Infect Chemother; 2012 Feb; 18(1):127-9. PubMed ID: 21814800
[TBL] [Abstract][Full Text] [Related]
7. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
8. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
9. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
10. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Jones RN; Stilwell MG; Rhomberg PR; Sader HS
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
Gagliotti C; Sarti M; Sabia C; Gargiulo R; Rossolini GM; Carillo C; Cassani C; Cipolloni AP; Pedna F; Rossi MR; Incerti SS; Testa G; Venturelli C; Moro ML
New Microbiol; 2011 Jan; 34(1):97-9. PubMed ID: 21344153
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
14. Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.
Delgado-Valverde M; Torres E; Valiente-Mendez A; Almirante B; Gómez-Zorrilla S; Borrell N; Corzo JE; Gurgui M; Almela M; García-Álvarez L; Fontecoba-Sánchez MC; Martínez-Martínez L; Cantón R; Praena J; Causse M; Gutiérrez-Gutiérrez B; Roberts JA; Farkas A; Pascual Á; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Feb; 71(2):521-30. PubMed ID: 26538507
[TBL] [Abstract][Full Text] [Related]
15. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
[TBL] [Abstract][Full Text] [Related]
17. Empiric antibiotic protocols for cancer patients with neutropenia: a single-center study of treatment efficacy and mortality in patients with bacteremia.
Kleinhendler E; Cohen MJ; Moses AE; Paltiel O; Strahilevitz J; Cahan A
Int J Antimicrob Agents; 2018 Jan; 51(1):71-76. PubMed ID: 28705670
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
19. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
Ratliff AR; Gentry CA; Williams RJ
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Fujimura S; Takane H; Nakano Y; Watanabe A
J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
